Assignee
JANUX THERAPEUTICS INC
US·4 granted patents·28 pending applications·8 citations·filing 2018–2025
Top patents by PatentIndex Score
32 records- 0194US11512113B2Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2021·Granted Nov 29, 2022·7 cites·25 claims
- 0288US12161724B2Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigensJANUX THERAPEUTICS INC·Filed 2022·Granted Dec 10, 2024·1 cites·21 claims
- 0381US2026001963A1Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigensJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0480US12433953B2Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigensJANUX THERAPEUTICS INC·Filed 2024·Granted Oct 7, 2025·0 cites·31 claims
- 0579US2026014267A1Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigensJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0678US2024376226A1Compositions and methods relating to tumor activated t cell engagersJANUX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0778US2025019403A1Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0872US2023348618A1Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigensJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0971US2023147782A1Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1070US11555078B2Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigensJANUX THERAPEUTICS INC·Filed 2021·Granted Jan 17, 2023·0 cites·26 claims
- 1170US2023270854A1Modified antibodiesJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1262US2023220105A1Tumor activated t cell engagers and methods of use thereofJANUX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1362US2023220109A1Compositions and methods relating to tumor activated t cell engagersJANUX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1462US2026049140A1Tumor activated antibodies targeting cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1561US2023357429A1Optimized antibodies targeting trop2 and uses thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1661US2023357447A1Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1760US2025154278A1Optimized antibodies targeting trop2 and uses thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1860US2024059790A1Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigensJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1959US2026049137A1Optimized antibodies targeting cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2058US2024254241A1Antibodies targeting egfr and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2158US2018339043A1Modified antibodiesJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2256US2024034814A1Half-life extending compositions and methodsJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2355US2024043536A1Peptide compositions and methods for anti-cd3 binding domainsJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2455US2024034806A1Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigensJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2554US2023406955A1Antibodies targeting her2 and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2654US2021115106A1Modified t cell receptorsJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2754US2024092931A1Antibodies targeting trop2 and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2854US2024043565A1Antibodies targeting psma and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2954US2023406937A1Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3054US2020385440A1Modified bispecific t cell receptorsJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3151US2025250339A1Antibodies targeting egfr and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3249US2025297017A1Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigensJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →